eligibility_summary
Eligible: confirmed CLL/SLL needing therapy, previously untreated, no TP53 aberrations, documented 11q and IGHV status, able to swallow oral meds. Exclude: active HBV/HCV, GI dysfunction affecting absorption (eg, gastric bypass/gastrectomy), other malignancy progressing or treated in past 3 years (except cured basal/squamous skin or carcinoma in situ), history of severe bleeding, not recovered from major surgery/ongoing complications.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3, randomized, first‑line CLL/SLL (no TP53 aberrations) comparing: 1) Nemtabrutinib (MK‑1026): an oral, small‑molecule, noncovalent/reversible BTK inhibitor (active vs WT and C481S BTK). Mechanism: blocks B‑cell receptor (BCR) signaling (BTK→PLCγ2→NF‑κB), reducing survival/proliferation/migration of malignant B cells. 2) Chemoimmunotherapy (investigator’s choice): FCR (fludarabine + cyclophosphamide + rituximab) or BR (bendamustine + rituximab, rituximab or biosimilars Truxima/Ruxience/Riabni). Mechanisms: - Fludarabine: purine analog antimetabolite inhibiting DNA polymerase/ribonucleotide reductase → impaired DNA synthesis/repair, apoptosis of lymphocytes. - Cyclophosphamide: alkylating agent causing DNA crosslinks. - Bendamustine: alkylating agent with antimetabolite features causing DNA crosslinks. - Rituximab/biosimilars: anti‑CD20 monoclonal antibodies mediating B‑cell depletion via ADCC, CDC, and apoptosis. Targets: malignant CD20+ B cells, BCR/BTK pathway, DNA replication/repair. Primary endpoint: progression‑free survival.